Home LiteratureArticle Details
PMID: 2684709 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S. Review

Type II diabetes, glucose "non-sense," and islet desensitization.

Diabetes ·Vol. 38 ·No. 12 ·1989-12-00 ·Pages 1501-5

Robertson RP

Abstract

A universal finding in hyperglycemic patients with type II (non-insulin-dependent) diabetes mellitus is that all share a common defect in glucose recognition resulting in abnormal insulin secretion by pancreatic islet beta-cells. This defect is 1) specific for glucose signals rather than global, 2) related to chronic hyperglycemia, and 3) partially reversible after brief treatment with insulin to induce normoglycemia and through use of other pharmacological agents without normalizing glucose levels. My perspective is that an essential component of this defect is secondary and may represent a state of homologous desensitization of the beta-cell secretory apparatus to glucose. Elucidation of the biochemical mechanism(s) of defective recognition of glucose signals by beta-cells--or glucose "non-sense"--in these patients will provide key insights into the pathogenesis of type II diabetes mellitus.

MeSH Terms
Diabetes Mellitus, Type 2/metabolism,physiopathology Glucose/metabolism Humans Hyperglycemia/physiopathology Insulin/metabolism Insulin Secretion Islets of Langerhans/metabolism
Chemicals
Insulin Glucose
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Robertson R P
Diabetes Center, University of Minnesota, Minneapolis 55455.
Article Info
Journal
Diabetes
Abbr.
Diabetes
ISSN
0012-1797
Published
1989-12-00
Pages
1501-5
Language
English
Region
United States
NLM ID
0372763
Subset
IM
Grants
NIDDK NIH HHS · R01-DK-38325 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com